Home › Trial NCT05271240
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Trial IDNCT05271240
- StatusRecruiting
- PhasePhase 3
- Study typeInterventional
- SponsorNorthwell Health
- Enrollment432
- Start date2022-04-27
- ConditionsGlioblastoma · Glioblastoma Multiforme · Glioma, Malignant · GBM · Brain Cancer · Glioblastoma, IDH-wildtype
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.